2 news items
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
APLS
7 May 24
by EMA is strictly procedural in response to the CJEU judgment and is not related to the pegcetacoplan data package
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
APLS
26 Apr 24
to the pegcetacoplan data package. Apellis will continue to work closely with EMA on the review of the pegcetacoplan marketing application
- Prev
- 1
- Next